Cargando…
Rediscovering Trazodone for the Treatment of Major Depressive Disorder
Trazodone is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs). The drug is approved and marketed in several countries worldwide for the treatment of major depressive disorder (MDD) in adult patients. In clinical studies, trazod...
Autores principales: | Fagiolini, Andrea, Comandini, Alessandro, Dell’Osso, Mario Catena, Kasper, Siegfried |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693429/ https://www.ncbi.nlm.nih.gov/pubmed/23192413 http://dx.doi.org/10.1007/s40263-012-0010-5 |
Ejemplares similares
-
Erratum to: Rediscovering Trazodone for the Treatment of Major Depressive Disorder
por: Fagiolini, Andrea, et al.
Publicado: (2013) -
Role of trazodone in treatment of major depressive disorder: an update
por: Fagiolini, Andrea, et al.
Publicado: (2023) -
Trazodone effects on [(3)H]-paroxetine and α(2)-adrenoreceptors in platelets of patients with major depression
por: Marazziti, Donatella, et al.
Publicado: (2010) -
A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder
por: Fagiolini, Andrea, et al.
Publicado: (2020) -
An Observational Pilot Study using a Digital Phenotyping Approach in Patients with Major Depressive Disorder Treated with Trazodone
por: Čermák, Jan, et al.
Publicado: (2023)